Peter Osborne Joins myoscience as Chief Financial Officer

Peter Osborne Joins myoscience as Chief Financial Officer

REDWOOD CITY, Calif., Sept. 16, 2013-- myoscience, inc. is pleased to announce the addition of Peter Osborne to the team as chief financial officer (CFO). Osborne has over 25 years of experience in high growth public and private companies, most notably with Hansen Medical and VNUS Medical Technologies, and most recently with SentreHEART, Inc.

"Peter has extensive experience in scaling the business, executing global strategy and implementing financial controls to position myoscience for continued success," said Clint Carnell, CEO of myoscience. "His leadership will help myoscience expand globally and with additional clinical indications."

Osborne led VNUS through dramatic revenue growth expanding to more than 350 employees and selling into more than 40 countries, culminating in its acquisition by Covidien in 2009. "It is exciting to be joining myoscience at this inflection point in their growth. The positive clinical benefits of Focused Cold TherapyTM experienced by patients and physicians is accelerating market adoption," said Osborne. "The current strategic needs of the company and my experience in fully realizing the value of innovative technologies fit perfectly to guiding the business to its next stage of commercial success."

About myoscience

Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold TherapyTM, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions. The myoscience technology has also been cleared in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com.

Suggested Articles

Biogen stunned the biotech world Tuesday when it said it would file aducanumab for approval. Now that the dust has settled, what are analysts saying?

Biocytogen uses chromosome engineering for the in situ replacement of mouse antibody genes with the human counterparts.

Eli Lilly is canning the lead program for the crown jewel of its $1.6 billion Armo buyout after the drug put up a poor showing in pancreatic cancer.